Drug plus clot removal for large vessel stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a stroke caused by a large blockage in the front part of your brain and are getting a clot-removal procedure within 24 hours.
- You are 18 or older and were independent before the stroke (could do daily tasks without help).
- Your brain scan shows a moderate-sized area of damage (infarct core between 10 and 100 mL) and enough surrounding brain tissue at risk.
- You do not have severe heart, liver, or kidney problems, a bleeding risk, or allergies to the study drug or contrast dye.
- You are not pregnant or breastfeeding, and you are willing to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a medicine called human urinary kallidinogenase (which improves blood flow to the brain) to standard clot-busting treatment (reteplase) helps people recover better from an acute stroke. It's for patients who arrive at the hospital within 4.5 hours of symptom onset and meet specific safety criteria.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests whether an experimental medication called human urinary kallidinogenase can help people recover better and faster after a recent stroke. The medication is given as an injection and is thought to improve blood flow to the brain, potentially helping with movement and daily function.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.